New drug cocktail shows promise for tough head and neck cancers

NCT ID NCT07618624

ENROLLING_BY_INVITATION Disease control Sponsor: Sun Yat-sen University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether giving a combination of three drugs (finotonlimab, cetuximab, and docetaxel) before surgery can shrink tumors in people whose head and neck cancer has come back after prior immunotherapy and chemotherapy. The goal is to see if this approach leads to fewer cancer cells remaining after surgery. The trial involves 42 adults with a specific type of head and neck cancer that can still be surgically removed.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEAD AND NECK CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

head and neck cancer Head and Neck Neoplasms head and neck squamous cell carcinoma Squamous Cell Carcinoma of Head and Neck

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEAD AND NECK CANCER RECURRENT HEAD AND NECK SQUAMOUS CELL CARCINOMA

Contacts and locations

Show contact details

Locations

Affiliated Cancer Hospital and Institute of Guangzhou Medical University

Guangzhou, Guangdong, China
Affiliated Hospital of Guangdong Medical University

Zhanjiang, Guangdong, China
Cancer Hospital of Shantou University Medical College

Shantou, Guangdong, China
Guangzhou First People's Hospital

Guangzhou, Guangdong, China
Shenzhen Second People's Hospital

Shenzhen, Guangdong, China
Sun Yat-sen University Cancer Center

Guangzhou, Guangdong, China
The First People's Hospital of Foshan

Foshan, Guangdong, China
The Third Affiliated Hospital of Sun Yat-sen University

Guangzhou, Guangdong, China
Zhujiang Hospital of Southern Medical University

Guangzhou, Guangdong, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.